MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial

Related Keywords

Germany , Boston , Massachusetts , United States , Canada , Munich , Bayern , Planegg , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Morphosys Agview , Exchange Commission , Us Communications , Linkedin , Xencor Inc , Twitter , Drug Administration , Financial Liabilities , Chief Executive Officer , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Investor Relations , Morphosys , Reports , Reliminary , 022 , Monjuvi , Product , Sales , Rovides , 023 , Financial , Guidance , Educes , Liability ,